ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025)

ARS Pharmaceuticals (SPRY) reported Finished Goods of $7.3 million for Q1 2025, up 39.49% sequentially from $5.2 million in Q4 2024.

ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025) Analysis & Trends

ARS Pharmaceuticals (SPRY) has 2 years of Finished Goods data on file, last reported at $7.3 million in Q1 2025.

For the quarter ending Q1 2025, Finished Goods changed N/A year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2025 stood at $7.3 million (changed N/A YoY), and the FY2024 full-year result was $5.2 million, changed N/A from the prior year.
Finished Goods climbed to $7.3 million in Q1 2025, from $5.2 million in the prior quarter.
In the past five years, Finished Goods ranged from a high of $7.3 million in Q1 2025 to a low of $5.2 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	ARS Pharmaceuticals	595.78 Mn	394.81 Mn	-

Download Data

Date	Value
Mar 31, 2025	7.27 Mn
Dec 31, 2024	5.21 Mn